Phase 2 Trial of Oral KVD824 in Preventing HAE Attacks to Open

Phase 2 Trial of Oral KVD824 in Preventing HAE Attacks to Open

304118

Phase 2 Trial of Oral KVD824 in Preventing HAE Attacks to Open

KalVista Pharmaceuticals announced plans to soon begin enrolling patients in KOMPLETE, a Phase 2 clinical trial testing its investigational oral therapy KVD824 in preventing swelling attacks in people with hereditary angioedema (HAE) at sites in Canada, Australia, and the U.K. “Over the past month we have made substantial progress in commencing KOMPLETE, our worldwide Phase 2 clinical trial of KVD824 as a potential oral prophylactic therapy for HAE. The regulatory submissions have been approved in Canada, Australia, and…

You must be logged in to read/download the full post.